chartexchange

Sera: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 16, 2026 5:45 PM EST

On its third-quarter 2026 earnings conference call, held on Nov. 4, 2026, Sera (NASDAQ:SERA) reported that test volume for PreTRM, its blood test that predicts preterm birth risk, increased approximately fivefold from the first quarter of 2026. Expanding state Medicaid coverage and physician adoption are driving early commercial scale for the maternal health company. Three key takeaways stand out for long-term investors. State Medicaid programs pay for roughly 40% to 43% of U.S. births, making government policy the primary catalyst for diagnostic adoption. Securing fee schedule pricing in major markets allows the business to convert regulatory mandates into high-volume, reimbursed patient volume. Continue reading

Read original article